$14m invested to create vaccine for debilitating periodontal gum disease



The company was set-up to develop and commercialise the research outputs of a long-running programme originating from the University of Melbourne working in collaboration with CSL.

The announcement was made at the official launch of the University’s Centre for Oral Health Research (COHR).

The Series A investment comes from the Medical Research Commercialisation Fund’s (MRCF) Biomedical Translation Fund, a Commonwealth-backed fund managed by Brandon Capital Partners, CSL Ltd., Australia’s largest biotechnology company, and the University of Melbourne.

Denteric will focus on developing a therapeutic vaccine for treating periodontal disease, a debilitating and painful form of gum disease which affects one in three people globally. The disease damages periodontal soft tissue and alveolar bones, which support teeth, due to an accumulation of bacteria.

Read full article on the Melbourne University website.